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emission tomography metrics 
and necrosis in classical Hodgkin 
lymphoma
X. U. Kahle1, f. M. Montes de Jesus2, t. c. Kwee3, t. van Meerten1, A. Diepstra4, S. Rosati4, 
A. W. J. M. Glaudemans  2, W. Noordzij2, W. J. plattel1 & M. Nijland1
Semiquantitative 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18f-fDG pet) 
parameters have been proposed as prognostic markers in classical Hodgkin lymphoma (cHL). In non-
Hodgkin lymphoma necrosis as assessed by 18F-FDG PET or computed tomography (CT) (necrosisvisual) 
correlates with an adverse prognosis. We investigated whether semiquantitative 18F-FDG PET metrics 
correlate with necrosisvisual, determined the incidence of necrosisvisual and explored the prognostic 
impact of these factors in cHL. From 87 cHL cases treated with ABVD, (escalated) BEACOPP or CHOP 
chemotherapy between 2010 and 2017, 71 had both a NEDPAS/EARL accredited 18F-FDG PET and a 
contrast enhanced CT scan. Semiquantitative 18F-FDG PET parameters were determined using Hermes 
Hybrid 3D software. Necrosisvisual, defined by photopenic tumor areas on 18F-FDG PET and attenuation 
values between 10 and 30 Hounsfield units (HUs) on CT, was assessed blinded to outcome. Univariate 
Cox regression survival analyses of progression free survival (PFS) were performed. Necrosisvisual was 
observed in 18.3% of cHL patients. Bulky disease (tumor mass >10 cm in any direction) (P = 0.002) 
and TLG (P = 0.041) but no other semiquantitative parameters were significantly associated with 
necrosisvisual. In exploratory univariate survival analysis for PFS the covariates IPS, bulky disease, MTV 
and TLG were prognostic, while necrosisvisual was not.
Classical Hodgkin lymphoma (cHL) is a B-cell neoplasm characterized by a minority of malignant Hodgkin-Reed 
Sternberg (HRS) cells in an inflammatory background1. Patients with cHL have an good prognosis with a 
long-term survival probability of over 90%. Nonetheless, about 10% of patients with early-stage (stage I-II) 
and 20–30% with advanced stage disease (III-IV) according to the Ann Arbor classification2, are refractory or 
relapse after first line therapy3. Therefore, it is important to improve prognostic and predictive models, in order 
to optimize treatment results and reduce therapy-related toxicity. Several prognostic models are used for clinical 
risk stratification, including the international prognostic score (IPS) for advanced stage disease, the European 
Organization for Research and Treatment of Cancer (EORTC) score or the German Hodgkin Study Group 
(GHSG) classification for early stage disease. New prognostic biomarkers for cHL include serum levels of the 
Thymus and Activation Regulated Chemokine (TARC)4–8 and tissue gene expression profiles (GEP)9,10. Although 
promising, these markers are currently not routinely used to guide treatment.
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Imaging markers evaluated in cHL have focused on metabolic tumor volume (MTV) as quantified by 
18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET)11–13. However, results on the prog-
nostic value of MTV in cHL are inconsistent14–16. Although efforts to standardize semiquantitative measurements 
have been made17,18, many study results are not comparable and so far no uniform cut-off values for the inter-
pretation of parameters such as MTV have been established19. The prognostic potential of total lesion glycolysis 
(TLG), defined as the product of mean standard uptake value (SUVmean) and MTV, was recently shown in relapsed 
or refractory cHL20 and early unfavorable cHL21.
Tumor necrosis can be observed in the center of fast growing tumor lesions, illustrating the proposed under-
lying pathophysiological mechanism, in which tumors outgrow the existing nutrient and oxygen supplies22,23. 
In non-Hodgkin lymphoma (NHL), necrosis as assessed by magnetic resonance imaging (MRI) and computed 
tomography (CT) correlates with high tumor volume and high clinical risk scores24. Tumor necrosis as assessed 
using 18F-FDG PET scans and CT imaging (necrosisvisual) has been shown to be an adverse prognostic factor in 
NHL25–28. Previously, a study of 76 cHL patients with a thoracic mass treated with MOPP-like regimens, reported 
necrosis as assessed with CT scans in 21% of cases, but no significant impact on length of remission or overall 
survival (OS)29. However, with the introduction of 18F-FDG PET into clinical routine, whole-body staging has 
significantly improved30, warranting for a new investigation into the prognostic impact of necrosisvisual. In contrast 
to novel semiquantitative imaging markers, necrosisvisual can be easily detected using 18F-FDG PET or CT scans 
and has a dichotomous outcome.
The aims of the current study were (I) to determine the incidence of necrosisvisual in cHL, (II) to evaluate its 
correlation with semiquantitative 18F-FDG-PET metrics, and (III) to explore the prognostic impact of these fac-
tors with regard to outcome.
Methods
Study design and case selection. For this retrospective single center study a consecutive series of 87 
patients with histologically confirmed cHL according to WHO classification 200831 were initially identified in 
the electronic healthcare database of the University Medical Center Groningen (UMCG). Cases of nodular lym-
phocyte predominant HL, composite lymphoma and Hodgkin-like immuno-deficiency-associated lymphomas 
were excluded. Patients were treated between 2010 and 2017 according to ESMO guidelines32,33. Patient with 
limited stage disease (stage I-II) received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with 
radiotherapy, whereas patients with advanced stage disease (stage III-IV) were treated with either full course 
ABVD or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone 
Figure 1. Flow chart illustrating the case selection procedure for this study; cHL = classical Hodgkin 
lymphoma; PET = positron emission tomography; CT = computed tomography.
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(escBEACOPP) (Supplementary Tables 1 and 2). Four patients with severe pre-existent lung disease were treated 
with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) to prevent bleomycin-mediated lung 
toxicity34.
Of the 87 patients 3 had only stand-alone diagnostic CT scans and were excluded from further anal-
ysis. In 13 cases acquisition methods of 18F-FDG PET/CT scans did not comply with guidelines specified by 
the “Netherlands protocol for standardization of 18F-FDG whole-body PET studies in multi-center trials” 
(NEDPAS)35 or “European Association of Nuclear Medicine Research Ltd.” (EARL) protocols36. Finally, a total of 
71 cases were eligible for analysis (Fig. 1). First and second order semiquantitative metrics were analyzed. Patients 
were stratified according to international prognostic score (IPS)37. End of treatment response was assessed by 
18F-FDG PET/CT scan. For PET scans a Deauville score of ≤3 was interpreted as complete metabolic response in 
the absence of new lesions. Treatment response was classified as complete remission (CR), partial response (PR), 
stable disease (SD), or progressive disease (PD) according to Lugano criteria38. All cases with relapse were histo-
logically confirmed. Follow-up was registered until February 2018. According to Dutch regulations, no medical 
ethical committee approval was required for this retrospective, observational study. A waiver was obtained from 
the medical ethics committee of the UMCG on November 13th 2018. All data were coded before analysis.
18F-FDG PET imaging. Integrated 18F-FDG PET/CT images were acquired on a Biograph mCT (Siemens 
Medical Systems, Knoxville, TN, USA) after a minimum fasting time of 6 h. Whole body images (from the base of 
the skull to the mid-thigh) were acquired 60 minutes after intravenous administration of 3MBq/kg 18F-FDG. PET 
image acquisition for patients between 60 and 90 kg bodyweight was performed in 7 bed positions of 2 minute 
emission scans. Patients with bodyweight below 60 were imaged for 1.5 minute and above 90 kg for 3 minutes 
per bed position. Integrated 18F-FDG PET/CT images were corrected for scatter and attenuation based on CT 
information and automatically fused through three-dimensional fusion software (Siemens). Raw data were recon-
structed through ultra-high definition (Siemens).
Semiquantitative analyses. Semiquantitative analyses were performed using the “Tumor Finder” applica-
tion and the Hermes Hybrid 3D (Hermes Medical Solutions AB, Stockholm, Sweden) software, as described pre-
viously39. Briefly, NEDPAS/EARL accredited 18F-FDG PET and low-dose CT files were loaded from the UMCG 
electronic database. A spherical 3 cm3 volume of interest (VOI) over the right lobe of the liver was used as a refer-
ence according to PERCIST 1.0 criteria40 and the “Tumor Finder” application automatically selected all VOIs with 
uptake ≥ 1.5 × mean SUV + 2 standard deviations (SDs) of this reference VOI. Volumes of high physiological 
uptake, not suspected for lymphoma were manually removed, while volumes suspected for disease involvement, 
but not automatically selected by the “Tumor Finder” application were selected manually using a threshold of 
Figure 2. 18F-FDG PET in a 21-year-old man with classical Hodgkin lymphoma. Coronal maximum intensity 
projection 18F-FDG PET shows a mediastinal tumor mass (A). Axial 18F-FDG PET with concomitant low-dose 
CT shows necrosisvisual with a photopenic area in the mediastinal tumor (B,C, arrows), with attenuation of 
around 18 HU on contrast-enhanced CT (D, arrow).
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≥2.5 SUV corrected for body weight (SUVbw). Semiquantitative measurements included maximum standard-
ized uptake value (SUVmax), SUVpeak, SUVmean, MTV and TLG. SUVmax was defined as the SUV of the maximum 
intensity voxel within a region of interest (ROI), SUVpeak as the spherical 1 cm3 VOI within the borders of a lesion 
with the highest average SUV, SUVmean as the average of SUV within a ROI, MTV as the total metabolically active 
volume of segmented tumor and TLG as the product of SUVmean × MTV (summed over all lesions). To be repre-
sentative of the entire lymphoma SUVmax/peak/mean are reported here as means calculated across all lesions.
CT imaging. Full-dose, intra-venous contrast enhancement, diagnostic CT scans of neck, chest and abdomen 
were acquired as part of an integrated 18F-FDG PET/CT. CT scans were acquired using different multidetector 
row (≥16-slice) CT scanners (Somatom Series, Siemens Healthineers, Erlangen, Germany). Presence of bulky 
disease was defined with lymphomatous lesion with a diameter of more than 10 cm in any direction, as assessed 
by full-dose, intra-venous contrast enhancement, diagnostic CT imaging.
Assessment of necrosisvisual. 18F-FDG PET and CT review assessment of necrosisvisual was performed by 
an experienced reader (TCK) who was blinded to follow-up findings, including patient outcome, as previously 
described41,42. Briefly, all 18F-FDG PET and CT scans were visually assessed for the presence of tumor necrosis, 
within any nodal or extranodal 18F -FDG-avid lymphomatous lesion. Necrosisvisual was considered present if there 
were photopenic tumor areas on 18F-FDG PET and/or tumor areas with attenuation values between 10 and 30 
Hounsfield units (HUs) on CT (Fig. 2).
Statistical analysis. Baseline characteristics and semi quantitative parameters were described according to 
the presence of necrosisvisual. Categorical variables were expressed as counts and percentages. Differences between 
two nominal variables were evaluated using Pearson’s Chi square or Fisher’s exact test (for expected counts ≤ 5). 
Continuous variables were expressed as median with range. Univariate logistic regression analyses were used to 
determine the association of established prognostic parameters (stage, IPS, bulky disease) and semiquantitative 
parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) with the presence of necrosisvisual. For survival anal-
ysis progression free survival (PFS) and overall survival (OS) were used as endpoints. PFS was defined as the 
time from diagnosis until death, histologically confirmed relapse or progression of disease (defined as increased 
Total (n = 71)
Necrosisvisual status
P-value
Absent (n = 58) Present (n = 13)
No. % No % No. %
Gender
0.31aMale 43 60.6 33 56.9 10 76.9
Female 28 39.4 25 43.1 3 23.1
Age
0.74b
Median (range) 36 (17–82) 39 (17–82)  30 (19–68)
Age ≤ 45 y 50 70.4 40 69.0 10 76.9
Age > 45 y 21 29.6 18 31.0 3 23.1
Histology
0.54b
NS 40 56.3 31 53.4 9 69.2
MC 7 9.9 7 12.1 0 0.0
LR 1 1.4 1 1.7 0 0.0
NOS 23 32.4 19 32.8 4 30.8
EBV†
0.71bNegative 45 63.4 35 60.3 10 76.9
Positive 14 19.7 12 20.7 2 15.4
B symptoms
0.12aNo 33 46.5 30 51.7 3 23.1
Yes 38 53.5 28 48.3 10 76.9
Treatment
0.24b
ABVD 55 77.5 47 81.0 8 61.5
BEACOPP 12 16.9 8 13.8 4 30.8
CHOP 4 5.6 3 5.2 1 7.7
Radiotherapy
1.0aNo 34 47.9 28 48.3 6 46.2
Yes 37 52.1 30 51.7 7 53.8
Table 1. Baseline characteristics of patients with classical Hodgkin lymphoma according to necrosisvisual status 
as assessed by 18F-FDG PET and CT. NS: nodular sclerosis; MC: mixed cellularity; LR: lymphocyte rich; NOS: 
not otherwise specified. aPearson’s Chi-squared test with Yates’ continuity correction. bFischer’s exact test for 
count data. †Missing in 12 cases.
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diameter of lesions on CT in combination with higher FDG-signal on PET or increased PET signal with increased 
serum TARC levels)43,44, whichever came first. OS was defined as time from diagnosis until death (from any 
cause). Surviving patients were censored at the last date of follow-up. Survival curves were estimated according to 
the Kaplan-Meier method. Cox proportional hazards model was used for univariate and bivariate survival anal-
ysis and results were reported as hazard ratio (HR), 95% confidence interval (CI) and P-value based on statistical 
Wald-test. A P-value of less than 0.05 indicated statistical significance. Continuous parameters such as MTV 
and TLG were dichotomized using the statistic median. Determination of an ideal cut-off via receiver operating 
characteristic (ROC) analysis was deliberately avoided due to the retrospective character of this study and the lack 
of a validation cohort19. All analyses were performed using R version 3.4.1 and R-studio version 1.0.153 software.
Ethics approval and consent to participate. According to Dutch regulations, no medical ethical com-
mittee approval was required for this retrospective, observational study. This study utilized already registered/
acquired medical information from patients, the use of which is regulated under the code for good clinical 
Total (n = 71)
Necrosisvisual status
Absent (n = 58) Present (n = 13)
No. % No. % No. %
Stage
I-II 43 60.6 35 60.3 8 61.5
III-IV 28 39.4 23 39.7 5 38.5
IPS†
0–2 (low risk) 50 70.4 42 72.4 8 61.5
3–7 (interm./high risk) 20 28.2 15 25.9 5 38.5
Bulky disease
No 54 76.1 49 84.5 5 38.5
Yes 17 23.9 9 15.5 8 61.5
SUVmax
Median (range) 7.1 (3.4–20.9) 7.0 (3.4–21.0)  7.9 (5.4–18.3)
SUVmean
Median (range) 4.2 (2.7–8.7) 4.2 (2.7–8.7)  4.2 (3.3–8.2)
SUVpeak
Median (range) 5.3 (2.7–17.1) 5.3 (2.7–17.1)  5.3 (4.1–15.7)
MTV
Median (range) 237.8 (3.8–1212) 206.7 (3.8–1212)  398.7 (56.9–1151)
TLG
Median (range) 1169 (12.1–8048) 1093 (12.1–5775)  2079 (346–8048)
Table 2. Known prognostic parameters and semiquantitative measures according to necrosisvisual status. 
†Missing in 1 case.
Figure 3. Dot plot showing the relation between metabolic tumor volume (MTV), total lesion glycolysis (TLG) 
and necrosis per investigated case (n = 71). Cases with necrosisvisual as determined by visual assessment of 18F-
FDG PET scans and CT are depicted in red (n = 13).
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practice in the Netherlands and does not require informed consent in accordance with Dutch regulations. A 
waiver was obtained from the medical ethics committee of the UMCG on November 13th 2018.
Results
Baseline patient characteristics. The baseline characteristics of the 71 patients are summarized in Table 1. 
The median age across the entire patient population was 36.5 years with a range from 17–82 years. A majority of 
patients was treated with the ABVD regimen (n = 55, 77.5%).
Semiquantitative parameters. The median SUVmax, SUVmean and SUVpeak were 7.1 (range 3.4–20.9), 4.2 
(range 2.7–8.7) and 5.3 (range 2.7–17.1), respectively (Table 2). SUV parameters showed a skewed distribution, 
with the majority of values lying below the mean (mean SUVmax = 8.7; mean SUVmean = 4.6; mean SUVpeak = 6.8). 
MTV (median = 237.8, range = 3.8–1212) and TLG (median = 1169, range = 12.1–8048) were highly varia-
ble among examined cases. Both MTV and TLG exhibited distributions skewed towards smaller values (mean 
MTV = 309.9 ml, mean TLG = 1747.7). The range of TLG became larger with greater volumes (MTV) (Fig. 3).
Necrosis. Necrosisvisual was observed in 13 of the 71 cases (18.3%). CT (n = 13; 100%) and 18F-FDG PET 
(n = 12; 92.3%) agreed on the presence of necrosis in 12 of the 13 cases (92.3%). In one case lesions with attenu-
ation values of 10–30 HU were observed on CT, however photopenic areas in 18F-FDG PET could not be distin-
guished due to low resolution of the 18F-FDG PET images. Of the examined prognostic parameters, bulky disease 
(OR = 8.5; 95% CI: 2.3–32.1; P = 0.002) and TLG (OR = 4.3; 95% CI: 1.1–17.2; P = 0.041) correlated with a higher 
risk for necrosisvisual (Fig. 3), while stage and IPS did not. All other semiquantitative parameters were not associ-
ated with necrosisvisual (Table 3).
Survival analysis. The median follow up was 42 months (95% CI; 34–60.7; IQR = 26.7–65.5). Twelve 
patients (16.9%) experienced an event as defined for PFS. Seven patients had a histologically confirmed relapse 
and 4 patients had progressive disease (two with evident increase in diameter (CT) and 18F-FDG signal (PET) 
and 2 with evident increase of 18F-FDG signal and subsequent increase in TARC levels). There were 2 treatment 
related deaths: One due to complications of first line therapy (death counted as PFS event), the other due to com-
plications of salvage therapy (one of the 4 patients with progressive disease). Two patients died due to lymphoma. 
The 5-year PFS and OS for the entire cohort was 80.1% (95% CI: 69.9–91.8%) and 93.9% (95% CI: 88.3–99.9%), 
respectively. In univariate analysis for PFS IPS, bulky disease, MTV and TLG were prognostic factors, whereas 
necrosis was not (HR = 2.8; 95% CI: 0.8–9.4, P = 0.096) (Table 4). Apart from MTV (HR = 5.7; 95% CI: 1.3–
26.2; P = 0.024) and TLG (HR = 5.5; 95% CI: 1.2–25; P = 0.028), all other semiquantitative parameters (SUVmax, 
SUVmean, SUVpeak) were not prognostic for PFS.





III-IV 0.9 0.27–3.2 0.9
IPS
0–2 1
3–7 1.75 0.5–6.2 0.39
Bulky disease
Absent 1
Present 8.53 2.3–32.1 0.002**
SUVmax
<Median 1
≥Median 1.13 0.34–3.8 0.85
SUVmean
<Median 1
≥Median 0.89 0.27–3.0 0.85
SUVpeak
<Median 1
≥Median 0.77 0.23–2.6 0.67
MTV
<Median 1
≥Median 2.68 0.74–9.7 0.13
TLG
<Median 1
≥Median 4.3 1.1–17.2 0.041*
Table 3. Univariate logistic regression analyses for the association of investigated parameters with the presence 
of necrosisvisual. *P < 0.05. **P < 0.01.
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Discussion
In this retrospective study we performed a semiquantitative 18F-FDG PET analysis and assessment of necrosis 
(necrosisvisual) by 18F-FDG PET and CT in cHL.
Necrosisvisual was observed in 18% of patients. Despite the additional use of 18F-FDG PET imaging the 
observed rate of necrosisvisual in the current study was slightly lower than the incidence reported by Hopper et al.45. 
This might be explained by the focus on thoracic lesions in the latter study. Since there was a 92% agreement 
between CT and 18F-FDG PET to detect necrosisvisual we cannot make any statement about the superiority of one 
modality over the other. Nonetheless, by using two independent modalities we can confirm that necrosisvisual is 
present in a significant part of the cHL population, despite the distinct pathophysiologic characteristics of cHL.
The majority of cells in cHL lesions are infiltrating immune cells which have different proliferative character-
istics than cancer cells46. However, the immune cell infiltration in cHL is a pathological process that is abnormal 
and extensive in nature46–48. In the physiological setting lymph nodes harbor a wide spread capillary bed which 
provides nutrients and oxygen for the reticular meshwork in which immune cell interaction takes place49. In cHL, 
the infiltration by a substantial amount of immune cells frequently distorts and alters this highly vascularized 
lymph node architecture50,51. Nevertheless, biological evidence from studies investigating the role of the cHL 
microenvironment, suggests that mast cells, tumor associated macrophages, mesenchymal stromal cells as well as 
HRS cells themselves might be able to induce and contribute to angiogenesis52. In the light of this evidence, one 
might hypothesize that differences in proliferative activity between individuals, as well as an imbalance between 
proliferative activity of HRS cells and the infiltrate within individuals might explain why we observed necrosisvisual 
in almost 1 out of 5 patients in our cohort.
Parameters derived from semiquantitative analysis of 18F-FDG PET scans have been suggested as potential 
markers in lymphomas53,54. We could confirm these findings, as baseline MTV and TLG were prognostic for PFS 
in univariate survival analysis. Several small studies have implied that MTV can be used as a prognostic marker 
for survival in cHL16,55–57. In addition, previous investigations have suggested baseline TLG as a potentially useful 
prognostic marker for survival in cHL20,54 and other lymphomas58–63. However, as mentioned earlier, inconsistent 
results19,64, the challenge of standardizing quantification65,66, as well as small study cohorts, raise doubts about the 
potential of MTV measurements in clinical practice. While in NHL attempts are being made to include standard-
ized semiquantitative analysis in prospective trials67, larger, prospective studies with standardized guidelines for 
semiquantitative analysis and appropriate validation cohorts for the determination of relevant cut-off values are 
needed to conclusively assess the role of semiquantitative measures in cHL19,57.





III-IV 3.0 0.9–10.0 0.072
IPS
0–2 1
3–7 4.12 1.3–13.1 0.016*
Bulky disease
Absent 1
Present 5.3 1.7–16.8 0.005**
Necrosisvisual
Absent 1
Present 2.8 0.8–9.4 0.096
SUVmax
<Median 1
≥Median 0.7 0.2–2.1 0.49
SUVmean
<Median 1
≥Median 0.5 0.2–1.7 0.28
SUVpeak
<Median 1
≥Median 0.7 0.2–2.1 0.49
MTV
<Median 1
≥Median 5.7 1.3–26.2 0.024*
TLG
<Median 1
≥Median 5.5 1.2–25.0 0.028*
Table 4. Univariate Cox-regression analyses for progression free survival. *P < 0.05. **P < 0.01.
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Our analyses demonstrate that necrosisvisual had no prognostic impact on PFSs and was strongly determined 
by the presence of bulky disease and TLG measures above the median. Since TLG had a significant impact on 
the presence of necrosis while MTV and SUVmean did not, this points at a group of individual cases in which the 
interplay between volume and metabolic activity determines the development of necrosis.
The concept of tumor necrosis as a prognostic marker is based on the notion that it can develop when tumors 
outgrow their metabolic supply68. The correlation between proliferation rate and tumor necrosis, as exhibited 
by solid tumors such as clear cell renal cell carcinoma69 and nodular cutaneous melanomas70, is often stated to 
support this hypothesis. Necrosis as determined by visual assessment of 18F-FDG PET and CT scans, has been 
identified as an independent adverse prognostic factor in NHL41,42,71,72. However, conflicting reports73,74, as well 
as findings suggesting a crucial role for necrosis-induced inflammation75,76 imply necrosis as one of the causes for, 
rather than the result of tumor growth77,78. The relationship between necrosis and tumor volume might thus be 
very different in the setting of cHL with its distinct microenvironment, characterized by an extensive background 
of inflammatory infiltrate79.
This study has several limitations. Intrinsic to analyses of data from patients with cHL, there is heterogeneity 
with regard to received treatment (ABVD, escBEACOPP and, radiotherapy). It is important to point out that sem-
iquantitative PET measures or the presence or absence of necrosis had no influence on treatment selection. Only 
71 patients had 18F-FDG PET scans eligible for semiquantitative analysis, thereby reducing the power of the study. 
However, while our survival analysis is exploratory in nature we were able to reproduce the prognostic impact 
of IPS, bulky disease, MTV and TLG, reflecting a representative patient population. In the light of recent studies 
using ROC-analysis to find ideal cut offs for subsequent analysis, it is important to note that in the current study 
median values of semiquantitative 18F-FDG PET parameters were used for the dichotomization of continuous 
covariates. While we are aware that dichotomization of continuous variables always leads to a loss of information 
and reduction in power80, this option was chosen to avoid the introduction of arbitrary “optimal” cut-off values, 
which, in the absence of a validation cohort, can often be too specific for the retrospectively analyzed patient 
population, leading to unwarranted conclusions19.
Conclusion
In this retrospective cohort study necrosisvisual, as assessed by 18F-FDG PET and CT, was observed in 18% of cHL 
patients. Tumor necrosisvisual was significantly associated with bulky disease and TLG. In exploratory survival 
analysis the semiquantitative 18F-FDG PET parameters TLG and MTV were prognostic with regard to PFS, while 
necrosisvisual was not. Additional research is required to investigate the biological and clinical implications of 
tumor necrosis in cHL. While our results suggest no significant prognostic impact for necrosisvisual, the role of 
semiquantitative 18F-FDG PET parameters should be validated in prospective studies.
Data Availability
All data generated or analyzed are in the current manuscript.
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